Susquehanna International Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-175,223
| Closed | -$3.33M | – | 11355 |
|
|
2019
Q1 | $3.33M | Buy |
175,223
+26,435
| +18% | +$429K | ﹤0.01% | 2984 |
|
|
2018
Q4 | $2.01M | Buy |
148,788
+11,490
| +8% | +$128K | ﹤0.01% | 3511 |
|
|
2018
Q3 | $1.52M | Buy |
+137,298
| New | +$1.37M | ﹤0.01% | 4449 |
|
|
2017
Q1 | – | Sell |
-47,645
| Closed | -$234K | – | 10912 |
|
|
2016
Q4 | $234K | Buy |
47,645
+36,429
| +325% | +$187K | ﹤0.01% | 8416 |
|
|
2016
Q3 | $56K | Buy |
+11,216
| New | +$57.4K | ﹤0.01% | 8094 |
|
|
2016
Q1 | – | Sell |
-80,611
| Closed | -$563K | – | 10449 |
|
|
2015
Q4 | $837K | Buy |
80,611
+37,091
| +85% | +$503K | ﹤0.01% | 5779 |
|
|
2015
Q3 | $804K | Sell |
43,520
-51,905
| -54% | -$1M | ﹤0.01% | 6196 |
|
|
2015
Q2 | $1.86M | Sell |
95,425
-46,386
| -33% | -$821K | ﹤0.01% | 4883 |
|
|
2015
Q1 | $2.49M | Sell |
141,811
-86,744
| -38% | -$1.46M | ﹤0.01% | 3882 |
|
|
2014
Q4 | $3.65M | Buy |
228,555
+200,491
| +714% | +$2.68M | ﹤0.01% | 3386 |
|
|
2014
Q3 | $353K | Sell |
28,064
-54,858
| -66% | -$782K | ﹤0.01% | 7778 |
|
|
2014
Q2 | $1.29M | Buy |
82,922
+6,503
| +9% | +$95.6K | ﹤0.01% | 5507 |
|
|
2014
Q1 | $1M | Sell |
76,419
-32,966
| -30% | -$516K | ﹤0.01% | 5520 |
|
|
2013
Q4 | $1.76M | Buy |
109,385
+84,660
| +342% | +$1.35M | ﹤0.01% | 4516 |
|
|
2013
Q3 | $411K | Sell |
24,725
-23,615
| -49% | -$349K | ﹤0.01% | 6738 |
|
|
2013
Q2 | $487K | Buy |
+48,340
| New | +$508K | ﹤0.01% | 6076 |
|
Other funds holding OSIR
Susquehanna International Group's OSIR Position: Q2 2019 in Review
Susquehanna International Group sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 175,223 shares — an estimated $3.33M sold.
Susquehanna International Group first reported a position in OSIR in Q2 2013 and held it in 16 quarters. The position peaked at $3.65M in Q4 2014. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Susquehanna International Group reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Susquehanna International Group sold 175,223 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $3.33M.
- Susquehanna International Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 16 quarters.
- Susquehanna International Group's Osiris Therapeutics, Inc. Common Stock position peaked at $3.65M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.